S. Heeger

1.5k total citations · 1 hit paper
32 papers, 1.2k citations indexed

About

S. Heeger is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hepatology. According to data from OpenAlex, S. Heeger has authored 32 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 7 papers in Hepatology. Recurrent topics in S. Heeger's work include Colorectal Cancer Treatments and Studies (15 papers), Lung Cancer Treatments and Mutations (11 papers) and Hepatocellular Carcinoma Treatment and Prognosis (7 papers). S. Heeger is often cited by papers focused on Colorectal Cancer Treatments and Studies (15 papers), Lung Cancer Treatments and Mutations (11 papers) and Hepatocellular Carcinoma Treatment and Prognosis (7 papers). S. Heeger collaborates with scholars based in Germany, Italy and United States. S. Heeger's co-authors include Carsten Bokemeyer, Eric Van Cutsem, Michael Schlichting, Ilhan Celik, Philippe Rougier, Claus‐Henning Köhne, Fortunato Ciardiello, Hubert Piessevaux, Sabine Tejpar and Marc Buyse and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics and Annals of Oncology.

In The Last Decade

S. Heeger

31 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials

2012 447 citations Carsten Bokemeyer, Eric Van Cutsem et al. European Journal of Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
S. Heeger Germany	14	895	402	242	235	221	32	1.2k
Claudia Maggi Italy	21	873 1.0×	360 0.9×	332 1.4×	261 1.1×	157 0.7×	36	1.3k
Annette Frost Germany	14	747 0.8×	493 1.2×	226 0.9×	462 2.0×	207 0.9×	29	1.4k
Marlies Michl Germany	18	697 0.8×	384 1.0×	148 0.6×	167 0.7×	243 1.1×	47	1.1k
Daniel Rauch Switzerland	20	711 0.8×	385 1.0×	185 0.8×	149 0.6×	156 0.7×	53	1.1k
N. Schleucher Germany	19	802 0.9×	610 1.5×	173 0.7×	598 2.5×	172 0.8×	32	1.6k
Yevhen Hotko Ukraine	13	1.2k 1.4×	609 1.5×	315 1.3×	206 0.9×	279 1.3×	26	1.4k
B. Mirtsching United States	12	1.1k 1.3×	459 1.1×	126 0.5×	182 0.8×	131 0.6×	27	1.3k
Hongnan Mo China	17	1.0k 1.1×	427 1.1×	148 0.6×	372 1.6×	103 0.5×	54	1.5k
Jean‐Luc Canon Belgium	11	1.6k 1.7×	691 1.7×	389 1.6×	314 1.3×	406 1.8×	12	1.8k
Catherine A. Azar United States	10	881 1.0×	215 0.5×	163 0.7×	220 0.9×	93 0.4×	13	1.1k

Countries citing papers authored by S. Heeger

Since Specialization

Citations

This map shows the geographic impact of S. Heeger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Heeger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Heeger more than expected).

Fields of papers citing papers by S. Heeger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Heeger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Heeger. The network helps show where S. Heeger may publish in the future.

Co-authorship network of co-authors of S. Heeger

This figure shows the co-authorship network connecting the top 25 collaborators of S. Heeger. A scholar is included among the top collaborators of S. Heeger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Heeger. S. Heeger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gaiser, Maria Rita, Sylvie Lorenzen, Kirsten Merx, et al.. (2019). Evaluation of EGFR inhibitor‐mediated acneiform skin toxicity within the double‐blind randomized EVITA trial: A thorough gender‐specific analysis using the WoMo score. Cancer Medicine. 8(9). 4169–4175. 4 indexed citations

Hofheinz, Ralf‐Dieter, Sylvie Lorenzen, Jörg Trojan, et al.. (2018). EVITA—a double-blind, vehicle-controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity. Annals of Oncology. 29(4). 1010–1015. 15 indexed citations

Ocvirk, Janja, S. Heeger, Philip McCloud, & Ralf‐Dieter Hofheinz. (2013). A review of the treatment options for skin rash induced by EGFR-targeted therapies: Evidence from randomized clinical trials and a metaanalysis. Radiology and Oncology. 47(2). 166–175. 47 indexed citations

Hartmann, J.T., Christian Kollmannsberger, Ingolf Cascorbi, et al.. (2012). A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer. Investigational New Drugs. 31(3). 661–668. 7 indexed citations

Pirker, Robert, J. R. Pereira, Aleksandra Szczęsna, et al.. (2012). Prognostic factors in patients with advanced non-small cell lung cancer: Data from the phase III FLEX study. Lung Cancer. 77(2). 376–382. 5 indexed citations

Trarbach, Tanja, et al.. (2012). Phase I study of matuzumab in combination with 5-fluorouracil, leucovorin and cisplatin (PLF) in patients with advanced gastric and esophagogastric adenocarcinomas. Investigational New Drugs. 31(3). 642–652. 13 indexed citations

Bokemeyer, Carsten, Eric Van Cutsem, Philippe Rougier, et al.. (2012). Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials. European Journal of Cancer. 48(10). 1466–1475. 447 indexed citations breakdown →

Tejpar, Sabine, Carsten Bokemeyer, Ilhan Celik, et al.. (2011). Kras mutations and outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. Annals of Oncology. 22. 3 indexed citations

Bokemeyer, Carsten, et al.. (2011). EFFICACY OF CHEMOTHERAPY plus CETUXIMAB ACCORDING TO METASTATIC SITE IN KRAS WILD-TYPE METASTATIC COLORECTAL CANCER: ANALYSIS OF CRYSTAL AND OPUS STUDIES. Annals of Oncology. 22. 2 indexed citations

10.

Pawel, Joachim von, Robert Pirker, J. R. Pereira, et al.. (2011). 9019 POSTER DISCUSSION Safety Analysis of Patient Subgroups Defined by Low and High Tumour Epidermal Growth Factor Receptor (EGFR) Expression in FLEX Study Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Receiving Chemotherapy With or Without Cetuximab as First-Line Therapy. European Journal of Cancer. 47. S598–S598. 2 indexed citations

11.

Koehler, Bruno Christian, Toni Urbanik, Binje Vick, et al.. (2009). TRAIL-induced apoptosis of hepatocellular carcinoma cells isaugmented by targeted therapies. World Journal of Gastroenterology. 15(47). 5924–5924. 31 indexed citations

12.

Schulze‐Bergkamen, Henning, Binje Vick, Toni Urbanik, et al.. (2008). Bcl-xL and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells. World Journal of Gastroenterology. 14(24). 3829–3829. 37 indexed citations

13.

Heeger, S.. (2007). Targeted Therapy of the Epidermal Growth Factor Receptor in the Treatment of Pancreatic Cancer. Recent results in cancer research. 177. 131–136. 6 indexed citations

14.

Hofheinz, Ralf‐Dieter, Karoline Horisberger, Christoph M. Woernle, et al.. (2006). Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer. International Journal of Radiation Oncology*Biology*Physics. 66(5). 1384–1390. 74 indexed citations

15.

Bischoff, Helge, Renate Haselmann, Carmen Timke, et al.. (2006). Treatment of non-small cell lung cancer with intensity-modulated radiation therapy in combination with cetuximab: the NEAR protocol (NCT00115518). BMC Cancer. 6(1). 122–122. 27 indexed citations

16.

Krempien, R., Marc Münter, Carmen Timke, et al.. (2006). Phase II study evaluating trimodal therapy with cetuximab intensity modulated radiotherapy (IMRT) and gemcitabine for patients with locally advanced pancreatic cancer [ISRCTN56652283]. Journal of Clinical Oncology. 24(18_suppl). 4100–4100. 4 indexed citations

17.

Kopp‐Schneider, Annette, Iris Burkholder, Peter Bannasch, et al.. (2006). Investigating the Formation and Growth of α-Particle Radiation-Induced Foci of Altered Hepatocytes: A Model-Based Approach. Radiation Research. 166(2). 422–430. 6 indexed citations

18.

Combs, Stephanie E., S. Heeger, Renate Haselmann, et al.. (2006). Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT) – phase I/II trial: study protocol. BMC Cancer. 6(1). 133–133. 77 indexed citations

19.

Krempien, R., Simeon Nill, Helmut Friess, et al.. (2005). Randomized phase II – study evaluating EGFR targeting therapy with Cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer – PARC: study protocol [ISRCTN56652283]. BMC Cancer. 5(1). 131–131. 54 indexed citations

20.

Hartung, G., S. Heeger, Thomas Bertsch, et al.. (2000). Adaptation and Clinical Evaluation of a Homogenous Enzyme Multiplied Immunoassay Technique (EMIT) for Drug Monitoring of a Methotrexate-Albumin Conjugate (MTX-HSA) in Humans. Oncology Research and Treatment. 23(4). 352–357. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact